Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $681 | $464 | $249 | $82 |
| % Growth | 46.6% | 86.4% | 204.9% | – |
| Cost of Goods Sold | $57 | $34 | $20 | $8 |
| Gross Profit | $624 | $431 | $229 | $74 |
| % Margin | 91.6% | 92.7% | 91.8% | 90.2% |
| R&D Expenses | $236 | $180 | $135 | $89 |
| G&A Expenses | $0 | $318 | $273 | $190 |
| SG&A Expenses | $504 | $410 | $359 | $273 |
| Sales & Mktg Exp. | $0 | $92 | $86 | $83 |
| Other Operating Expenses | $0 | $0 | -$1 | -$2 |
| Operating Expenses | $741 | $590 | $492 | $359 |
| Operating Income | -$117 | -$159 | -$264 | -$286 |
| % Margin | -17.1% | -34.3% | -105.8% | -349.6% |
| Other Income/Exp. Net | $43 | $20 | $7 | $2 |
| Pre-Tax Income | -$74 | -$139 | -$256 | -$284 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$75 | -$140 | -$256 | -$284 |
| % Margin | -11% | -30.1% | -102.9% | -347.7% |
| EPS | -0.72 | -1.46 | -2.72 | -3.5 |
| % Growth | 50.7% | 46.3% | 22.3% | – |
| EPS Diluted | -0.72 | -1.46 | -2.72 | -3.5 |
| Weighted Avg Shares Out | 103 | 96 | 94 | 81 |
| Weighted Avg Shares Out Dil | 103 | 96 | 94 | 81 |
| Supplemental Information | – | – | – | – |
| Interest Income | $43 | $20 | $7 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$117 | -$159 | -$263 | -$285 |
| % Margin | -17.1% | -34.2% | -105.6% | -349% |